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Background: Merkel cell polyomavirus (MCPyV) and trichodysplasia spinulosa-associated polyomavirus (TSPyV) are
recently found pathogens causing two rare skin disorders, Merkel cell carcinoma (MCC) and trichodysplasia
spinulosa (TS). MCC is proportionally common in the elderly and most often is associated with immunosuppression.
TS is a folliculocentric infection seen in patients in an immunocompromised state. Little or no baseline information
exists, however, on the prevalences of these two viruses among the elderly. Epidemiologic data on this population
could help in understanding their natural biology. We wished to determine the occurrences and blood levels of
MCPyV and TSPyV DNAs among the elderly and any association between the prevalences of their corresponding
antiviral IgG antibodies.
Methods: From 394 hospitalized elderly individuals (age ≥65 years) with respiratory symptoms, cardiovascular, and
other diseases, we studied 621 serum samples by four different real-time quantitative (q) PCRs, two for the DNAs of
MCPyV and two for TSPyV. The IgG antibodies for both viruses among 481 serum samples of 326 subjects were
measured with enzyme immunoassays (EIAs), using as antigen recombinant virus-like particles (VLPs).
Results: Of the 394 patients, 39 (9.9%) were positive at least once for MCPyV DNA by the LT PCR, and 33 (8.4%) by
the VP1 PCR, while 6 (1.5%) were positive by both PCR assays. In general, the viral DNA copy numbers were low. In
sharp contrast, no TSPyV DNA was detectable with qPCRs for the corresponding genomic regions. The IgG
seroprevalence of MCPyV was 59.6% and of TSPyV, 67.3%.
Conclusions: MCPyV DNA, unlike TSPyV DNA, occurs in low copy number in serum samples from a notable
proportion of aging individuals. Whether this reflects enhanced viral replication possibly due to waning immune
surveillance, and is associated with increased MCC risk, deserves exploration.
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Merkel cell polyomavirus (MCPyV) causes Merkel cell
carcinoma (MCC) [1], an aggressive skin cancer that is
highly unusual before age 50 [2,3]. The elderly, immuno-
suppressed individuals and post-transplant patients, and
Caucasians exposed to excessive UV light, are at increased
risk [4,5]. MCPyV infection, defined by serology or detec-
tion of viral DNA, is prevalent [6-10]. The presence of* Correspondence: reza.sadeghi@helsinki.fi
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reproduction in any medium, provided the orMCPyV DNA at high copy number and tumor-specific
mutations in MCPyV genomes appear in tumor tissue but
not in healthy tissue [11]. Interestingly, similar truncating
mutations have been described in chronic lymphocytic
leukemia (CLL) [12].
Ubiquitous presence of MCPyV DNA has become
apparent in cutaneous swabs from clinically healthy sub-
jects at prevalences of 40 to 60% [13,14]. Besides in skin,
viral DNA has been detected at lower frequencies also in
respiratory secretions, on the oral and anogenital mucosa,
and in the digestive tract [9]. Furthermore, by examining
fetal autopsy samples, we obtained data to rule outl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mode of transmission remains to be elucidated and could
involve cutaneous, fecal-oral, mucosal, or respiratory
routes. Moreover, the presence of the MCPyV genome has
also been reported in peripheral blood mononuclear cells
(PBMC) from adult HIV/AIDS patients without MCC and
from healthy blood donors at low DNA copy numbers
[16,17]. Among healthy subjects, MCPyV exposure as
measured by serum antibodies to viral capsid proteins
appears to be wide [18,19]. Tolstov et al. showed seropre-
valences of 43% among children aged 2 to 5 years, and
80% among adults older than 50 [18]. We and others also
observed frequent primary exposure to MCPyV during
childhood and a trend toward increasing seroprevalence
among adults [20,21].
Trichodysplasia spinulosa-associated polyomavirus
(TSPyV), the eighth human polyomavirus, was detected
by rolling circle amplification (RCA) after the identifica-
tion of human polyomaviruses 6 and 7 in 2010 [14,22].
Trichodysplasia spinulosa (TS) is a rare, disfiguring skin
condition that affects immunocompromised solid organ
transplant patients and lymphocytic leukemia patients,
universally involving the central face [23-25]. Its disco-
verers further showed the presence of TSPyV DNA
in eyebrow hairs of 4% of 69 renal transplant patients
without TS and a lack of TSPyV DNA in human piloma-
tricomas [22,26]. High prevalence (100%) and load
(∼106 copies/cell), of TSPyV DNA in TS lesions, and
abundant expression of TSPyV VP1 in the affected hair
follicle cells evidenced that active TSPyV infection is asso-
ciated with TS and apparently essential in its pathogenesis
[27]. Two recent serology studies showed that TSPyV
circulates widely in the human population (prevalences of
10% in small children to 80% in adults), and primary
exposure is extensive in childhood, beginning at age 1 or 2
years [28,29]. TSPyV positivity of nasopharyngeal and
fecal samples from an immunosuppressed child (heart
transplant recipient) without TS suggests respiratory or
fecal–oral route of transmission [30].
Data regarding MCPyV, TSPyV and aging are scarce.
Additional epidemiological deta on elderly persons,
regarding serum antibody responses and genome preva-
lence is needed. To our knowledge the present collection
of sera is the first sizeable material that has been studied
for the presence of MCPyV and TSPyV in aging indivi-
duals in order to determine whether and to what extent
these viruses appear in this population at elevated risk of
MCC. We studied a large number of serum samples
from aging (≥65 years) representatives of the general
population by real-time quantitative (q) PCRs for the
DNAs of MCPyV and TSPyV by using primer sets direc-
ted against the genes encoding large-T antigen 1 (LT1)
and viral protein 1 (VP1). In addition, the IgG antibodies
for the two viruses were measured with EIAs by using asan antigen the corresponding VP1 virus-like particles
(VLPs).
Methods
Study populations
For determination of MC and TS polyomavirus DNAs
and IgG antibody seroprevalences, 621 blood samples
were collected from 394 hospitalized senior citizens with
respiratory symptoms or suspected pneumonia, cardio-
vascular, and other diseases in the city hospital of Turku,
Finland, between July 2007 and April 2009. The criteria
for sampling were age 65 years or older, disease requir-
ing hospitalization, and a written assignment from the
patient or trustee. Patients who came for a short elective
operation were excluded from the study. The study
protocol was approved by the Ethics Committee of
Turku University Hospital.
Sample collection
Eligible patients were informed of this study at hospital
entry. After signing the consent, the patients or trustees
were interviewed, and hospital records reviewed for clin-
ical history. Nasopharyngeal swab samples (flocked swab,
520CS01, Copan, Brescia, Italy) and serum samples were
collected at hospital entry and after two weeks or at dis-
charge for detection of acute infections. The swabs in
dry tubes and serum samples were stored at -80°C. Dis-
posable gloves were used to prevent contamination.
DNA extraction
The DNA Mini kit (Qiagen, Crawley, UK) was used
according to the manufacturer's instructions for nucleic-
acid extraction. A negative control of molecular biology-
grade water was extracted and included in the PCR
between sets of 10 samples. MCPyV DNA is known to
occur on virtually all environmental surfaces that have
been in contact with human skin [31]. During sample
processing, in addition to routine PCR precautions, we
always wore double disposable gloves and frequently
changed them as well as avoided touching anything ex-
cept pipettes and used aliquoted reagents.
Real-time PCR assay for detection of MCPyV and TSPyV
Two published primer sets targeting conserved
sequences in the MCPyV genome, the large T antigen
(LT) gene, and the viral capsid protein (VP1) gene
(Table 1) were used according to Goh et al [32]. PCR
was done with the ABI PRISM 7700 Sequence Detector
(Applied Biosystems) thermal cycler using the TaqMan
universal PCR master mix (PE Applied Biosystems), and
the settings were 52°C for 2 min, 95°C for 10 min, fol-
lowed by 45 cycles of 95°C for 10 s and 60°C (LT assay)
or 58°C (VP1 assay) for 1 min. For both assays, control
plasmids were cloned from amplicons of PCR-positive
Table 1 Primers and probes used to detect TSPyV and MCPyV
Virus Primers & probes sequence (50–>30) Region Amplicon size
MCPyV FWD-CCACAGCCAGAGCTCTTCCT LT 140
REV-TGGTGGTCTCCTCTCTGCTACTG
FAM-TCCTTCTCAGCGTCCCAGGCTTCA-TAMRA
MCPyV FWD-TGCCTCCCACATCTGCAAT VP1 59
REV-GTGTCTCTGCCAATGCTAAATGA
6FAM-TGTCACAGGTAATATC-MGBNFQ
TSPyV FWD-TGTGTTTGGAAACCAGAATCATTTG LT 140
REV-TGCTACCTTGCTATTAAATGTGGAG
FAM-TTCTTCTTCCTCCTCATCCTCCACCTCAAT-BHQ1
TSPyV FWD-AGTCTAAGGACAACTATGGTTACAG VP1 140
REV-ATTACAGGTTAGGTCCTCATTCAAC
FAM-ACAGCAGTGACCAGGACAAGCCTACTTCTG-BHQ1
Tail Sequence AACTGACTAAACTAGGTGCCACGTCGTGAAAGTCTGACAAGTGTCTCTGCCAA TGCTAAATGA
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Cloning Kit (Thermo Scientific). Serial dilutions of the
plasmids allowed determination of assay sensitivity. In
each assay, five copies per reaction were reproducibly
positive, corresponding to 200 copies/mL of serum. For
contamination control, in addition to DNA extraction
controls, we included 30 controls of molecular biology-
grade water per run of 54 DNA extractions. The MCPyV
qPCR products were purified for automated sequencing
with the High Pure PCR product purification kit
(Roche). The resulting DNA sequences were aligned by
means of the Basic Local Alignment Search Tool
(BLAST) against the MCPyV sequences in GenBank.
As the MCPyV VP1 PCR product was too short for dir-
ect sequencing, we added a 40 base pairs (bp) nonspecific
nucleotide tail [34] (Table 1) in addition to a poly(C) to the
50 end of the sequencing primers to accomplish a product
of 110 bp. The neutral sequence is a randomly generated
sequence not matching any sequence in a BLAST search.
For detection of TSPyV, we applied published qPCRs,
with primer pairs targeting the VP1 and LT genes [22] but
changed the quenching dye TAMRA to BHQ1 on the 30
base of the probes (Table 1). While annealing was done
for 15 s at 62°C, the cycling conditions were otherwise
identical to those of the MCPyV protocol. For use as posi-
tive controls and to determine assay sensitivities due to
the lack of known positive samples, the TSPyV LT and VP
regions were synthesized and cloned into pUC57 by
GenScript (Piscataway, NJ, USA). The detection limit of
each assay was 5 target copies per reaction, corresponding
to 200 copies/mL of serum.
MCPyV and TSPyV serology
MCPyV and TSPyV IgG antibodies in 481 serum sam-
ples from 326 subjects (available from the initial 621samples from 394 subjects) were measured by in-house
enzyme immunoassays (EIA) based on virus protein 1
(VP1) virus-like particles (VLPs) showing no antigenic
cross-reactivity between the two viruses [21,29]. Briefly,
recombinant baculovirus genomes containing the MCPyV
and TSPyV VP1 gene sequence were generated by using
the Bac-to-Bac expression system in S. frugiperda (Sf) 9
insect cells. The VLPs were biotinylated and used as anti-
gens in an indirect EIA assay, as described [21,29]. The
cut off values defining a positive IgG result were 0.150 and
0.240 OD units at 492 nm for MCPyV and TSPyV,
respectively [21,29].
Results
Patient characteristics
The median age of the 394 patients was 82 years (range
65 to 100), and from those 226 (57%) were female. Sera
tested in this study were from three groups of patients;
Group I consisted of 111 serum samples obtained from
patients with respiratory disease (chronic obstructive
pulmonary disease, asthma, other lung disease). Group
II included 209 serum samples from patients with
cardiovascular disease (stroke, coronary artery disease,
myocardial infarction, heart failure, heart dysrhythmia).
Group III included 301 samples from patients with other
diseases (hypertension, cancer, depression, dementia,
rheumatic disease) (Table 2).
MCPyV and TSPyV qPCR
MCPyV DNA detection by using qPCR for 621 serum
samples of the 394 patients produced 72 positive results;
39 (9.9%) patients were positive by the LT assay, 33
(8.4%) by the VP1 assay, and 6 (1.5%) by both assays
(Table 3). Concerning all these numbers, a positive result
had been obtained at least twice upon reproduction. The
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had very high Ct values (average Ct values LT/VP1 =
38.67/39.78), as did the six patients sera that were posi-
tive with both PCRs (average Ct values LT/VP1 = 37.08/
37.18), indicating low viral loads. qPCR displayed Ct
values in the 35.88 – 40 and 36.18 – 40 ranges for LT
and VP assays, respectively. One-fifth of the PCR pro-
ducts were sequenced (13 of the LT gene and 12 of the
VP1 gene). All were confirmed to be MCPyV and
showed a 100% identity to each other and also to those
of the previously described MCPyV strain sequences
with no deletions or other mutations. The serum sam-
ples were also tested with the corresponding TSPyV
qPCRs. No TSPyV DNA was emerged in any subject.
Associations between clinical characteristics and MCPyV
DNA positivity
When we examined the association between MCPyV-
DNA positivity in serum and clinical characteristics
(Table 2), VP1-PCR positivity was significantly and posi-
tively associated with chronic respiratory disease (p = 0.023,
Table 2). Univariable logistic regression was used to ana-
lyse the association between patient characteristics and
virus etiology. Statistical significance was established at
the level of P < 0.05. For statistics SAS Enterprise Guide
4.3 (SAS Institute Inc., Cary, NC, USA) was used. No
associations appeared between LT1-PCR positivity and
clinical condition.
MCPyV and TSPyV serology
In addition, we examined by VLP-EIAs 481 correspond-
ing serum samples from 326 elderly patients for MCPyV
and TSPyV IgG antibodies. Of the 481 available sera 171
were single without follow-up sample. The IgG sero-
prevalence of 326 patients for MCPyV was 59.6%, and
for TSPyV, 67.3%. These seroprevalences did not signifi-
cantly change with increasing age (Figure 1) and we
found no significant correlation between antibody levels
and increasing age. Antibody titres in assays based on
VLPs of MCPyV showed no correlation to the titres in
similar TSPyV assays. With only two exceptions among
326 individuals, the antibody levels were almost identicalTable 2 Associations between patient characteristics and MCP
Disease group Sample number
Respiratory disease1 111
Cardiovasevular disease2 209
Other disease3 301
Logistic regression analyses, the reference groups were those without respiratory, c
1Respiratory disease = chronic obstructive pulmonary disease, asthma, other lung d
2Cardiovascular disease = stroke, coronary artery disease, myocardial infarction, hea
3Other disease = hypertension, cancer, depression, dementia, rheumatic disease.
4MCPyV VP1 =Merkel cell polyomavirus viral protein 1.
5MCPyV LT1 =Merkel cell polyomavirus Large T Antigen1.in follow-up sera taken two weeks apart, ruling against
recent immunogenic infections with MCPyV or TSPyV.
Among the 72 MCPyV PCR positive patients 15 were
MCPyV VP1 IgG negative.Associations between clinical characteristics and
seroprevalence
Associations between seroprevalence and the diseases
were calculated from clinical data available for 326
patients. The MCPyV IgG seroprevalence in the respira-
tory disease group was not higher than in the group
without respiratory disease, OR 1.316 (0.793 – 2.182). In
cardiovascular disease group the TSPyV IgG seropreca-
lence was lower than in a group without cardiovascular
disease, OR 0.559 (0.321 – 0.973). No other associations
were found. In the logistic regression analyses, the refer-
ence groups were those without respiratory, cardiovascu-
lar, or other diseases respectively.Discussion
Our results show the occurrence of MCPyV DNA rather
commonly in sera from the elderly. The source of viral
DNA in their blood is unknown. As the previously
identified polyomaviruses JCV and BKV do occur at
increased frequencies in blood and lymphoid tissue dur-
ing host immunosuppression, and the same has been
reported in some studies for the newly discovered KIPyV
and WUPyV [35-37], it is tempting to speculate that
with increasing age MCPyV may reactivate more often,
causing viremia, especially as hematolymphoid cells may
harbour MCPyV [38]. The potential in elderly individuals
for MCPyV to replicate and be released into serum under
special circumstances deserves further investigation.
A study of 840 serum samples for MCPyV revealed
only one sample from a leukemic child to be PCR-
positive; more often viral DNA was detected in tonsillar
tissue of adults [33]. In a study of 635 NPA samples with
exactly the same primers and probes as ours, more
adults (particularly the elderly) than children were
MCPyV positive [32]. Our high prevalence of MCPyV
DNA among the elderly is in agreement with theyV LT1 and VP1 DNA positivity
4MCPyV VP1 odds ratio
(95% confidence interval)
5MCPyV LT1 odds ratio
(95% confidence interval)
2.40 (1.13 – 5.11) 0.630 (0.277 – 1.435)
0.57 (0.27 – 1.21) 1.348 (0.638 – 2.850)
0.47 (0.19 – 1.12) 1.129 (0.418 – 3.048)
ardiovascular, or other diseases respectively.
isease.
rt failure, heart dysrhythmia.
Table 3 Age distribution of MCPyV infected patients
Age group
(years)
No. of sample
tested
MCPyV Positive
patients %
(VP1)
MCPyV Positive
patients %
(LT1)
60-70 36 0.4 0.0
71-80 174 4.0 6.3
81-90 307 7.1 7.5
91-100 104 3.8 4.8
Total 621 8.4 9.9
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more frequently among the elderly [32].
As in several other studies, viral DNA was detectable
in low copy numbers, however, making the interpret-
ation of positive results challenging [17,32,39,40].
According to others’ positivity criteria concerning VP1
and LT PCRs [32,39,40], we concluded six samples as
being unequivocally positive for MCPyV. However, all 25
amplicons from the LT or VP PCRs contained the cor-
rect sequence, and the 437 negative controls (62 for
DNA extraction plus 375 for qPCR) were always nega-
tive, suggesting that also the single-PCR positives were
true positives. Divergent sequences among the circulat-
ing viruses could perhaps cause false negativity in the
PCRs, or the low viral amounts could lead to stochastic
variance in detection.
Among the 72 MCPyV PCR-positive patients 15 were
MCPyV VP1 IgG negative. One possible explanation for
this difference, in light of the ubiquitous presence of
MCPyV DNA in superficial skin, is contamination of the
needle piercing the skin during sampling. This deserves
to be explored.
Of note, MCPyV detection rates by LT1, LT3, and
VP1-region primers have invariably shown mutual dis-
cordance among samples of various entities [1,32,39,40].
We used primers from both the VP1 and LT regions of60
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Figure 1 Age-dependent prevalences of MCPyV and TSPyV
antibodies. Both MCPyV and TSPyV seroprevalences are very similar
in all age groups of the elderly.MCPyV and reasoned that the presence of both genes,
capsid VP1 and oncogenic LT, would better indicate the
presence of infectious virions, hence the stringent criter-
ion of coupled LT and VP1 positivity for MCPyV detec-
tion by these assays. Interestingly, we found a positive
association between MCPyV VP1-PCR but not LT1-PCR
positivity and chronic respiratory disease. However, any
conclusions about MCPyV pathogenicity in the respira-
tory tract cannot be drawn without epidemiologic sup-
port and further investigation with different sample
types. Furthermore, it is difficult to resolve whether the
higher prevalence by the VP1 assay was due to increased
sensitivity or to a difference in genome identity sequences
among the MCPyV strains.
The prevalence of MCPyV antibody positivity increases
with age throughout life [18-21,41,42]. Our MCPyV ser-
ology results also showed that the majority of the elderly
have been exposed to MCPyV with similar seropreva-
lences in all subgroups.
Taken together, MCPyV DNA appeared in serum in
low copy numbers in many aging individuals. Serological
results have shown that MCPyV infection is common,
but only rarely leads to MCC. The presence of the virus
alone is insufficient for tumor development. While MCC
tumors require specific mutations (both T antigen trun-
cation and genomic integration) [1], and in most cases
immunosuppression, additional risk factors and viral
changes are required before clinically apparent MCC
emerges.
TSPyV is a ubiquitous virus that frequently infects the
general population. To determine the exposure history
and activity of infection among the aging, we conducted
a survey by molecular and serologic tests. In contrast to
MCPyV, no TSPyV DNA appeared in the elderly sub-
jects’ sera. For one explanation of these negative PCR
findings, TSPyV viremia may be of short duration.
Whether TSPyV infections are able to persist is un-
known, but likely, based on results for other polyoma-
virus infections. Our TSPyV IgG data confirmed two
recent serologic reports showing TSPyV circulation in
the general population [28,29]. The seroprevalence we
found for TSPyV among the elderly was high (>60%)
with no variation according to advancing age, and com-
parable with that for MCPyV.
Conclusions
These results indicate that MCPyV DNA, unlike TSPyV
DNA, occurs in low copy numbers in serum in a notable
proportion of aging individuals. Whether the enhanced
viral replication in our elderly participants is a reflection
of waning immune surveillance and is correlated with
increased MCC risk deserves exploration. Antibodies
against MCPyV and TSPyV occurred at high rates in
serum samples from the elderly.
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